Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 4 October 2023

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of the Commonwealth of Australia, was introduced to regulate the supply, advertising, and importation of therapeutic goods to ensure public health and safety. The Act establishes a framework for the quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and blood products. One of its primary policy objectives is to protect the health and safety of the public by ensuring that therapeutic goods available in Australia meet the necessary standards. The Act allows the Therapeutic Goods Administration (TGA) to issue licences for the manufacture of therapeutic goods, and it provides mechanisms for the revocation of these licences if certain conditions are not met. This ensures that only entities adhering to the prescribed standards can manufacture therapeutic goods within Australia. The recent Gazette C2023G01125 from the Department of Health and Aged Care under the TGA highlights the revocation of licences for several manufacturers at their own request, reinforcing the regulatory oversight of therapeutic goods in the country.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities that manufacture, supply, or import therapeutic goods in Australia. This includes businesses, corporations, and individuals who engage in the production or distribution of goods that fall within the scope of the Act. The Act pertains to a broad range of therapeutic goods, including medicines, medical devices, blood, and tissues. The legislation imposes requirements and standards to ensure the quality, safety, and efficacy of these products, thus protecting public health. The Act's jurisdiction is national, applying across all states and territories of Australia, and it sets a unified framework for the regulation of therapeutic goods. However, certain activities may be subject to exclusions or exemptions based on specific provisions within the Act or through subordinate instruments, which can extend or restrict the application of the legislation. For example, some medical devices may be exempt from certain requirements if they are intended for personal use or research purposes. The revocation of manufacturing licences, as demonstrated in the Gazette, is a specific application of the Act, whereby the Therapeutic Goods Administration can remove the authority of entities to manufacture therapeutic goods under certain conditions.

Key Provisions

The Therapeutic Goods Administration (TGA), acting under the authority of the Therapeutic Goods Act 1989, has published a notification concerning the revocation of several licences for the manufacture of therapeutic goods. The relevant section of the Act, Section 41(1)(d), allows the Secretary to revoke a manufacturer’s licence by written notice. The revocations in question concern the licences held by Safflower Pty Ltd (MI-2014-LI-01411-1), Hive & Wellness Australia (MI-2015-LI-11403-1), Ultra Mix (Aust) Pty Ltd (MI-09032006-LI-001151-11), and Air Liquide Australia Limited (MI-23122004-LI-000330-1). These revocations have been carried out at the request of the manufacturers themselves. Under the Therapeutic Goods Act, the revocation of a manufacturer’s licence imposes specific obligations on the affected entities. Once a licence is revoked, the manufacturers are no longer authorised to manufacture therapeutic goods. This means they must cease any ongoing manufacturing activities and comply with any additional instructions or conditions stipulated by the TGA. Failure to adhere to these obligations could lead to further regulatory action. The Therapeutic Goods Act also includes provisions for offences and penalties in cases of non-compliance. While the document does not detail specific offences or penalties related to these revocations, the Act generally allows for enforcement actions that could include fines and, in severe cases, criminal charges. The penalties for breaches of the Act can vary widely depending on the nature and severity of the offence, with some potential maximum penalties reaching into the millions of dollars for corporate entities. The TGA has the authority to take legal action against manufacturers who do not comply with the Act’s requirements, which could result in significant financial and reputational harm.